🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer NCT06123988NA3 sites📍 Phoenix📍 Miami📍 Boston University of Miami · Tests: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: SHR- A1811 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site📍 Zhejiang Zhejiang Cancer Hospital · Tests: Antitumor treatment plan A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. NCT07340424EARLY Phase 11 site📍 Jinan Xiaorong Sun · Tests: 225Ac-TR2205 Injection FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy Scarless Advanced Breast Extended Oncoplasty: The ScarABEO Study NCT06906237n/a1 site📍 Padova Istituto Oncologico Veneto IRCCS Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer NCT07401537Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Extended-Dose Interval Immunotherapy, Standard-Dose Interval Immunotherapy Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy NCT06998108Phase 31 site📍 Beijing BeBetter Med Inc · Tests: BEBT-209 capsules, BEBT-209 Placebo capluses, Fulvestrant Injection ARX788 in HER2-positive Metastatic Breast Cancer Patients NCT06663748Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: ARX788 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185Phase 41 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Pyrotinib, Trastuzumab, Taxanes, Capecitabine A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791Phase 130 sites📍 Newport Beach📍 Stanford📍 Miami Eli Lilly and Company · Tests: LY4337713 The COMPASSION Study NCT06507930NA1 site📍 Boston Dana-Farber Cancer Institute · Tests: Telehealth Hospice Visits Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. NCT07299409Phase 21 site📍 Vancouver Nathalie Levasseur · Tests: Sacituzumab Govitecan (SG) TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer NCT07047365Phase 375 sites📍 Bengbu📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2930+ chemotherapy, Trastuzumab+ chemotherapy SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site📍 Beijing Akeso · Tests: AK112, Nab-paclitaxel, Placebo Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor NCT05536128Phase 21 site📍 Seoul Seoul National University Hospital · Tests: Olaparib, Fulvestrant A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy